

Anti-MUC1, Mouse-Mono (014E) < Anti-Mucin1 >

Catalog NO. FDV-0012A/B

Research use only, not for human or animal therapeutic or diagnostic use.
This product has been commercialized under the license from Kagoshima University.

Product Background

MUC1 (Mucin-1; also PEM, PEMT and Episialin), a mucin-type glycoprotein, has been associated with cancer progression and metastasis. Initially polypeptide chain of MUC1 is cleaved into two pieces, MUC1-N and MUC1-C (Figure 1). MUC1-N includes cleavage sites and a tandem repeat (TR) domain which has the potential for extensive *O*-glycosylation. On the other hand, MUC1-C has a lot of splicing variants. The most of the commercially available MUC1 antibodies fail in the detection of the MUC1 variants. Clone 014E antibody is raised against common region of MUC1 splicing variants (Figure 1). Clone 014E antibody recognizes most variant forms of MUC1. Recent studies show that clone 014E antibody succeeded in detecting scirrhous gastric cancer (ref. 1, 5) and pancreatic cancer (ref. 4, 5)




Figure 1 Structure of MUC1 and epitope of clone 014E

Description

Catalog Number: FDV-0012A/B

Size: 25 µL (FDV-0012A), 100 µL (FDV-0012B)

Lot No.: see vial label

Host Species and Clonality: Mouse Monoclonal

Clone name: 014E

Specificity: Human Mucin1/MUC1

Isotype and Subclass: IgG1, kappa

Formulation: Mouse Ascites (Contain 50% Glycerol, Not contain any preservative)

Verified Species Reactivity: Human * Note: Other species not tested.

Immunogen: Synthetic Peptide, corresponding to Common Region in Cytoplasmic Tail Domain (CTD) of Human MUC1 (CRYVPPSSSTRSPYEKVSAG)

Storage: -80°C (Avoid repeated freeze-thaw cycles.)

Application and Recommended usage

- Western blotting 1/2,500-1/5,000
- Immunohistochemistry 1/2,500-1/5,000 (Paraffin)


*Optimal working dilutions should be determined experimentally by each laboratory for each application

Reference

1. Yonezawa, *et al.*, *Gastric Cancer*, **15**, 370-381 (2012) A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach
2. Yokoyama, *et al.*, *BMC Cancer*, **12**, 67 (2012) The application of methylation specific electrophoresis (MSE) to DNA methylation analysis of the 5' CpG island of mucin in cancer cells
3. Kitamoto, *et al.*, *Oncogene*, **32**, 4614-4621 (2013) MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors
4. Yokoyama, *et al.*, *PLOS ONE*, **9**, e93760 (2014) Diagnosis of Pancreatic Neoplasms Using a Novel Method of DNA Methylation Analysis of Mucin Expression in Pancreatic Juice

Application Data

Immunohistochemical Staining



Sample: Human stomach cancer (Adenocarcinoma Grade I)

Retrieval method: HIER (pH6.0 / 30 min)

(heat-induced epitope retrieval method)


Dilution: 1:2,500

Detection reagent: ImmPRESS Reagent, Anti-Mouse Ig
(Vector Laboratories, #MP-7402-15)

Chromogen reagent: ImmPACT DAB Peroxidase Substrate
(Vector Laboratories, #SK-4105)

Western Blotting

Capan-1 HEK293



Sample: 5 µg cell lysate in each lane.

Left: Capan-1 (Human pancreatic cancer derived. MUC1 positive)

Right: HEK293 (MUC1 negative)

Dilution: 1:2,500

Secondary antibody: Anti-Mouse IgG, Goat-Poly, HRP

(Kirkegaard & Perry Laboratories, #074-1516)

Chemiluminescence Substrate: SuperSingal West Pico (Pierce)

Detection: GeneGnome (Syngene) with 1min exposure.

Disclaimer/免責事項

This product has been commercialized by Funakoshi Co., Ltd. based on the results of academic research, and the advertisement text, figures and manuals (hereinafter "Product information") have been prepared based on published research reports on September, 2016. The academic interpretation at the time of creation of the Product Information may change in accordance with future developments in the relevant research field and expansion of various scientific findings, and the latest version and certainty of the Product Information are not guaranteed. The specifications of this product and the Product Information are subject to change without notice. Please contact us for the latest information.

本製品は学術研究成果を基にフナコシ株式会社が製品化したもので、2016年9月時点における公開研究報告を基に広告文章およびマニュアル(以下、製品資料)を作成しています。今後の当該研究分野の発展および各種学術知見の拡大にともない、製品資料作成時の学術的解釈が変更になる可能性があり、最新性・確実性を保証するものではありません。また、本製品の仕様および製品資料を予告なく変更する場合がございます。最新の情報に関しましては、弊社までご確認いただけますようお願い申し上げます。



E-mail Newsletter
Sign Up

Japanese



English




Related products

Catalog No.	Product name	Target	Application
FDV-0023	Anti-Laminin α 3B, Human, Mouse-Mono (F7)	Laminin α 3B	IHC, WB, IP, ELISA
FDV-0024	Anti-Laminin α 3A, Human, Mouse-Mono (BG5)	Laminin α 3A	IHC, WB, IP, ELISA
FDV-0025	Anti-Laminin γ 2 N-terminal fragment, Human, Mouse-Mono (P2H)	Laminin γ 2 N-terminal fragment	IHC, WB, ELISA
FDV-0026	Anti-Laminin 511, Human, Mouse-Mono (12D)	Trimeric Lm511 structure	IHC, WB, IP, ELISA


Anti-Laminin α 3B (F7) #FDV-0023

Sample : normal human skin
 Arrow head : vascular basement membrane
 Arrow : epithelial basement membrane




Anti-Laminin α 3A (BG5) #FDV-0024

Sample : normal human skin
 Arrow : epithelial basement membrane



Anti-Laminin γ 2 N-terminal fragment (P2H) #FDV-0025

Sample : human normal mammary gland (left),
 human breast cancer (right, T=tumor)



Anti-Laminin 511 (12D) #FDV-0026

Sample : human normal mammary gland
 Arrow head : vascular basement membrane
 Arrow : mammary gland basement membrane

